James Healy
General Partner & President @ Sofinnova Investments
Menlo Park, United States
James Healy is a Series B investor at Sofinnova Investments in Menlo Park focused on Biotechnology and Pharmaceutical. Dr. Healy is a General Partner at Sofinnova Ventures. Dr. Healy has over 15 years of experience in biomedical research and development. He joined Sofinnova Ventures as a General Partner in 2000. Dr. Healy was an early investor and board member of Cellective (acquired by MedImmune), CoTherix (acquired by Actelion), Novacea (Nasdaq: NOVC), andInterMune (Nasdaq: ITMN). He also serves on the boards of directors of several private companies. In the pharmaceutical industry, he held a manufacturing position at Bayer Pharmaceuticals (Miles) and helped guide the discovery group at ISTA Pharmaceuticals prior to its initial public offering. Dr. Healy authored or co-authored numerous research articles and reviews, including three papers published in Nature. He began his private equity career at Sanderling.Dr. Healy earned B.A.s in Molecular Biology and Scandinavian Studies from the University of California at Berkeley, where he graduated with Distinction in General Scholarship, Honors, and received a Departmental Citation. Dr. Healy received his M.D. from Stanford University’s School of Medicine through the Medical Scientist Training Program, and earned his Ph.D. in Immunology from Stanford University, where he was a Beckman Scholar and received a bursary award from the Novartis Foundation. Dr. Healy teaches a course on entrepreneurship at Stanford University, and is an active member of the BIO-NVCA Working Group.
- Total investments:
- 25
- Last investment:
- Lead investor:
- 40%
Last updated:
For AI agents: llms.txt
Industries James Healy invests in
Stages James Healy invests in
Countries James Healy invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 15 (60%)
- Pharmaceutical 10 (40%)
- Health Care 8 (32%)
- Therapeutics 8 (32%)
- Medical 7 (28%)
Stage
- Series B 10 (40%)
- Series A 6 (24%)
- Series C 4 (16%)
- Series D 2 (8%)
- Series F 1 (4%)
Country
- United States 11 (44%)
- Switzerland 3 (12%)
- United Kingdom 2 (8%)
- Belgium 1 (4%)
- Ireland 1 (4%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Seaport Therapeutics
|
Seaport Therapeutics operates as a clinical stage biopharmaceutical company. | $100M / Series A / Apr 09, 2024 | |
BioAge Labs
|
BIOAGE discovers and develops drugs to treat aging and associated diseases. The company's primary initiative, azelaprag, is an oral APJ agonist on track for Phase 2 trials in conjunction with tirzepatide to potentially become a groundbreaking treatment for obesity in the elderly. | $170M / Series D / Feb 13, 2024 | |
Rapport Therapeutics
|
Rapport Therapeutics operates as a clinical-stage biotechnology company, that discovers and develops precision medicines for neurological disorders. Rapport Therapeutics describes relationships that are defined by understanding, communication, teamwork, and trust. | $150M / Series B / Aug 23, 2023 | |
ArriVent
|
ArriVent is dedicated to accelerating the global development of innovative biopharmaceutical products. | $155M / Series B / Dec 29, 2022 | |
CinCor Pharma
|
CinCor is a clinical-stage biopharmaceutical company with a mission to advance promising clinical candidates toward marketing approval. CinCor’s focus is on cardiovascular, metabolic and kidney diseases. CinCor has program is CIN-107, a novel aldosterone synthase inhibitor. | $143M / Series B / Oct 12, 2021 | |
|
CinCor Pharma
|
CinCor is a clinical-stage biopharmaceutical company with a mission to advance promising clinical candidates toward marketing approval. CinCor’s focus is on cardiovascular, metabolic and kidney diseases. CinCor has program is CIN-107, a novel aldosterone synthase inhibitor. | $50M / Series A / May 14, 2019 | |
Karuna Therapeutics
|
Karuna Therapeutics is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions. | $68M / Series B / Mar 18, 2019 | |
ObsEva
|
ObsEva SA is a Swiss-based, speciality biopharmaceutical company dedicated to the development of innovative drugs for women's reproductive medicine. ObsEva's main focus is on therapies for preterm labor.ObsEva was founded in November 2012, by Ernest Loumaye MD, PhD and André Chollet PhD. Ernest Loumaye is a specialist in femalereproductive medicine with 20 years of experience in the biopharmaceutical industry. Ernest Loumaye was previously Co-Founder and CEO of PregLem SA, a successful biopharmaceutical company which was acquired by Gedeon Richter in 2010. André Chollet is specialist in medicinal and pharmaceutical chemistry with more than 30 years of experience in diverse positions in the biopharmaceutical industry, including in Biogen, GSK and Merck Serono. André Chollet was responsible for the preterm labor program at Serono before the acquisition of the company by Merck KGaA. | $60M / Post-IPO Equity / Oct 10, 2017 | |
Iterum Therapeutics
|
Iterum Therapeutics is a clinical-stage pharmaceutical company that develops significantly differentiated anti-infectives. It aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum’s first product is a novelanti-infective compound that has demonstrated potent in-vitro activity vs. a wide variety of gram-negative, gram-positive, and anaerobic bacteria resistant to other antibiotics. | $40M / Series A / Mar 24, 2016 | |
|
ObsEva
|
ObsEva SA is a Swiss-based, speciality biopharmaceutical company dedicated to the development of innovative drugs for women's reproductive medicine. ObsEva's main focus is on therapies for preterm labor.ObsEva was founded in November 2012, by Ernest Loumaye MD, PhD and André Chollet PhD. Ernest Loumaye is a specialist in femalereproductive medicine with 20 years of experience in the biopharmaceutical industry. Ernest Loumaye was previously Co-Founder and CEO of PregLem SA, a successful biopharmaceutical company which was acquired by Gedeon Richter in 2010. André Chollet is specialist in medicinal and pharmaceutical chemistry with more than 30 years of experience in diverse positions in the biopharmaceutical industry, including in Biogen, GSK and Merck Serono. André Chollet was responsible for the preterm labor program at Serono before the acquisition of the company by Merck KGaA. | $69.9M / Series B / Nov 23, 2015 | |
| See all 25 investments → | |||
Co-Investors
About Sofinnova Investments
Sofinnova Ventures has partnered with entrepreneurs to secure initial funding, build successful teams, win key customers, and navigate acquisitions and IPOs. Sofinnova Ventures invests in Life Science and Technology start-ups. Their professionals are seasoned business operators, possessing deep domain and investment expertise. They know how to helpentrepreneurs build successful, global businesses.
Sofinnova Investments Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Jakob Dupont
Executive Partner
|
|||
|
James Healy
General Partner & President
|
|||
Jonathan Leff
Executive Partner, Private Equity
|
|||
Lesley Weber
San Diego Office Manager & EA
|
|||
Maha Radhakrishnan
Executive Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does James Healy invest in?
James Healy invests primarily in Biotechnology, Pharmaceutical and Health Care startups, most often at Series B and Series A stage. Most of the 25 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact James Healy?
Public channels for James Healy include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did James Healy last invest?
The most recent investment recorded for James Healy closed in Apr 2024. Shizune tracks 25 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
